By Dezan Shira & Associates
Editor: Tongyu Zhang
Upgrading science and technology innovation is a critical component of China’s 13th Five Year Plan covering the years 2016-2020, as the Chinese government aims to upgrade its tech capabilities. As part of this effort, on December 27, 2016, the Ministry of Finance (MOF), General Administration of Customs (GAC), and State Administration of Taxation (SAT) issued a joint notice (Cai Guan Shui  No.70) to standardize the duty-free import process of scientific and technological research equipment by scientific research institutions, technology development institutions, and schools.
Meanwhile, since being published in 2015, the two notices regarding deduction of R&D expenses (Cai Shui  No. 119 and SAT announcement  No. 97) were implemented in 2016. Therefore, now is a particularly relevant time to consider R&D related tax incentive policies for foreign-invested enterprises (FIEs) to review for effective tax planning.
Support of duty-free imports for science and technology innovation
Regarding foreign-invested R&D institutions in China, Notice No. 70 is applicable for those approved as foreign-invested R&D centers by provincial level authorities of commerce, finance and taxation, as well as local administration of customs.
According to the Notice, the import of scientific research, sci-tech development, and teaching supplies, which domestic suppliers cannot manufacture or for which they are unable to meet performance requirements, are exempt from import duties and import VAT. In addition, teaching books, materials, and relevant scientific research imported by scientific research institutes and schools, are exempt from import VAT. Note that the list of duty-free items may be reviewed within the announcement, Cai Guan Shui  No. 72.
Considerations for additional deduction policies of R&D expenses
Scope of R&D activities
R&D activities refers to systematic activities that an enterprise conducts to obtain and apply new science and technology knowledge creatively or substantially to improve its technologies, product (services), and processes.
However, as the definition of R&D activities is rather vague, Notice No. 119 uses a ‘negative list’ form to exclude activities and certain industries (as listed below) that do not apply to the pre-tax additional deduction policies.
- Conventional upgrades of the enterprise’s products (services);
- Direct application of certain technological research results;
- Technical support activities provided by the enterprise to its customers following commercialization;
- Repetitive or simple changes to existing products, services, technologies, materials, or processes;
- Market surveys or management studies;
- Quality control, testing and analysis, repair and maintenance in industry (service) process; and
- Research in social sciences, arts, or humanities.
RELATED: Audit and Financial Services from Dezan Shira & Associates
- Tobacco manufacturing;
- Lodging and food and beverage (F&B);
- Wholesale and retail;
- Real estate;
- Leasing and commercial services; and
Deductible R&D expenses
If R&D expenses incurred by an enterprise in its R&D activities have not formed intangible assets and are included in the current period’s profit or loss, 50 percent of such R&D expenses will be deducted from the taxable income amount of the current year. If intangible assets are formed, pre-tax amortization will be made based on 150 percent of the costs of the intangible assets.
The specific scope of R&D expenses include:
- Staff and labor expenses consisting of salaries, pensions and insurance of personnel engaging in R&D activities directly, and the service fees of external R&D personnel;
- Direct costs include materials, fuels and power expenses directly consumed by R&D activities and relevant manufacturing, purchasing or testing expenses for different stages of the R&D procedure;
- Depreciation of instruments and equipment used for R&D activities;
- Amortization of intangible assets used in R&D activities;
- Design fees for new products, fees for formulation of new processes, clinical trial fees for new drugs, and onsite testing fees for exploration and development technologies;
- Other expenses directly related to R&D activities, such as technical books and materials expenses, expenses for evaluation of R&D results and so on. Note that the total amount of these expenses shall not exceed 10 percent of the total amount of R&D expenses allowed for additional deduction.
For expenses incurred by R&D activities carried out by an external organization or individual entrusted by the enterprise, 80 percent of the actual amount shall be included in the entrusting party’s R&D expenses and allowed for additional deduction. However, expenses of R&D activities carried out by an overseas entrusted entity are not able to apply to additional deduction.
In the case of a project with high technical requirements and large investment which requires centralized R&D by an enterprise group, such a group may, based on the principles of matching corresponding rights and obligations as well as expenses and gains, share the actually incurred R&D expenses among benefiting member enterprises to allow the related enterprises to compute their respective additional deduction.
Declaration and filing of R&D expenses deduction
Enterprises should submit a “Filing Form for Enterprise Income Tax Incentives” and the R&D project documents to complete filing with the tax authorities no later than the annual computation and settlement tax declaration, and retain the following materials for future inspection:
- Proposal and approved resolution for the independent, entrusted, or cooperative R&D project;
- Composition of the organization or project team for the R&D project, as well as name list of the R&D personnel;
- Contract for the R&D project, which should be registered with the science and technology administrative authorities;
- Explanation on distribution of expenses of staff undertaking R&D activities and instruments, as well as equipment and intangible assets used for these activities;
- Balance sheet of R&D projects, breakdown of distribution of R&D expenses, and the actual benefit-sharing ratio;
- Subsidiary ledger for R&D expenditure;
- Expert opinions issued by local science and technology administrative authorities; and
- Other materials stipulated by the provincial tax authorities.
In consideration of China’s economic and political environment, it is now reasonable for FIEs to evaluate the gains and losses of relocating some advanced-technological business activities in China, such as R&D research and high-tech manufacturing. Apart from the tax incentives, FIEs can also enjoy the relatively lower labor cost for skilled workers and professional researchers.
Nevertheless, FIEs should pay attention to the implementation of the additional deduction of R&D expenses for two main reasons. First, R&D activities are complex, covering the full stages of business procedure. Secondly, identification of R&D expenditure is indistinct in practice, with taxation authorities maintaining a level of administrative discretion. Therefore, it is important for enterprises to keep in contact with local taxation authorities, as well as seek opinions from professional advisors.
Asia Briefing Ltd. is a subsidiary of Dezan Shira & Associates. Dezan Shira is a specialist foreign direct investment practice, providing corporate establishment, business advisory, tax advisory and compliance, accounting, payroll, due diligence and financial review services to multinationals investing in China, Hong Kong, India, Vietnam, Singapore and the rest of ASEAN. For further information, please email email@example.com or visit www.dezshira.com.
Stay up to date with the latest business and investment trends in Asia by subscribing to our complimentary update service featuring news, commentary and regulatory insight.
Dezan Shira & Associates Brochure
Dezan Shira & Associates is a pan-Asia, multi-disciplinary professional services firm, providing legal, tax and operational advisory to international corporate investors. Operational throughout China, ASEAN and India, our mission is to guide foreign companies through Asia’s complex regulatory environment and assist them with all aspects of establishing, maintaining and growing their business operations in the region. This brochure provides an overview of the services and expertise Dezan Shira & Associates can provide.
An Introduction to Doing Business in China 2017
Doing Business in China 2017 is designed to introduce the fundamentals of investing in China. Compiled by the professionals at Dezan Shira & Associates in January 2017, this comprehensive guide is ideal not only for businesses looking to enter the Chinese market, but also for companies who already have a presence here and want to keep up-to-date with the most recent and relevant policy changes.
New Considerations when Establishing a China WFOE in 2017
In this edition of China Briefing, we guide readers through a range of topics, from the reasons behind foreign investors’ preference for the WFOE as an investment model, to managing China’s new regulations. We discuss how economic transformations have favored the WFOE, as well as the investment model’s utility, and detail key requirements that businesspeople need to examine before initiating the WFOE setup process. We then walk investors through the WFOE establishment process, and, finally, explain the new and idiosyncratic “Actual Controlling Person” regulation.